Emalex develops new treatments in
neurological movement and fluency disorders

Emalex develops
new treatments
for rare
and orphan
neurological
conditions

Emalex Biosciences develops treatments for central nervous system movement disorders and fluency disorders. Our current focus is developing ecopipam, an investigational medicine, for Tourette Syndrome and stuttering.

OUR COMMITMENT

CLINICAL TRIALS

DRUG PIPELINE

PARTNERSHIPS

Emalex Biosciences develops treatments for central nervous system movement disorders and fluency disorders. Our current focus is developing ecopipam for Tourette Syndrome and stuttering.

OUR COMMITMENT

CLINICAL TRIALS

DRUG PIPELINE

PARTNERSHIPS

Emalex Biosciences develops treatments for central nervous system movement disorders and fluency disorders. Our current focus is developing ecopipam for Tourette Syndrome and stuttering.

OUR COMMITMENT

CLINICAL TRIALS

DRUG PIPELINE

PARTNERSHIPS